41 results about "Sterol" patented technology

The present invention relates to a temperature-responsive in situ gelling composition comprising an amphiphilic triblock copolymer of polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-PPO-PEO), a water-soluble hydrophilic polymer, wherein the composition further comprises at least one lipid agent. The lipid agent is selected from the group consisting of a phospholipid, a sterol, a glyceride, a fatty acid or ester and derivative, a fatty alcohol, a cholesterol and derivative or a combination of more than one lipid agent. The present invention further relates to a vascular embolization agent comprising the temperature-responsive in situ gelling composition.

A method for inducing an immune response in an individual to treat or prevent a disease or condition is provided, the method comprising administering a vaccine comprising lipid nanoparticles encapsulating nucleic acids encoding antigen proteins, peptides, or fragments thereof, a neutral lipid content of 30% to 70% molar ratio, sterols or derivatives thereof, and 5 to 50% molar ratio of ionizable cationic amino lipids, and a hydrophilic polymer-lipid conjugate present at a lipid content of 0% to 5% molar ratio, wherein administration of the lipid nanoparticles results in an immune response in an individual against the antigen protein, peptide, or fragment thereof expressed by mRNA, wherein each % molar ratio of lipid content relative to the total lipid content of the lipid nanoparticles is measured. This disclosure also provides vaccine compositions and the use of such compositions in inducing an immune response in an individual.

The present application provides a liposome having a double-layer membrane structure and use thereof. The liposome comprises a double-layer lipid membrane formed from (a) a phospholipid, (b) dipotassium glycyrrhizinate or a cationic surfactant, and (c) a polyoxyethylene sterol ether having a hydrophobic end embedded in the double-layer lipid membrane. The liposome of the present application has excellent stability and can be stably present in a formulation form. Furthermore, a liposome having a double-layer lipid membrane structure with excellent stability can be obtained without using a polyol.

The present application relates to the technical field of microbial feed additive, and discloses a feed lactic acid bacteria additive and a preparation method thereof.The preparation method comprises the following steps: taking Lactobacillus plantarum and / or Enterococcus faecalis as a bacterial strain to activate and expand culture, taking agricultural and sideline product waste as a substrate to obtain mature fermentation liquor through deep liquid fermentation; mixing the mature fermentation liquor with a composite protective agent containing double essential oil, chitosan, theabrownin and porous silicon dioxide to obtain a semi-dry granule core through granulation and low-temperature pre-drying; and coating the semi-dry granule core with a κ-carrageenan / konjac glucomannan / plant sterol ester composite gel, and drying and packaging to obtain a finished product.The double essential oil, chitosan and theabrownin jointly form a full-spectrum active antibacterial system; the elastic composite gel outer layer realizes dual protection of liquid water and water vapor; the porous silicon dioxide actively maintains low water activity of the granule to prevent the lactic acid bacteria from recovering in advance; and the product has high viable count, strong heat and acid resistance, and excellent storage stability.

The present disclosure provides a yeast composition enriched in at least one vitamin and / or in at least one sterol that can be used to provide antioxidant activity. The yeast composition can be used to prevent or limit the oxidation of an edible or a drinkable product. The yeast composition can be used to increase the robustness of a fermentative organism during a fermentation. The yeast composition can be used to provide a source of nutrition to a fermentative organism during a fermentation.

The invention relates to a composition comprising at least 50 mg / g of one or more omega-3 fatty acids, at least 10 mg / g of one or more xanthophylls, at least 1 mg / g of one or more sterols and at least 2 μg / g of one or more phycoprostanes, and to the use of said composition in particular as a food supplement for the prevention of the onset of cognitive disorders.

Provided herein are aminosterol compounds with modified pharmacokinetic profiles. Also provided herein are methods of treating disease, such as obesity, equine laminitis, equine metabolic syndrome, or cancer with the aminosterol compounds.

This invention belongs to the field of testing and analysis technology, and discloses a method for rapidly extracting and detecting the content of various terpenoids and sterols in rubber grass. The specific steps are as follows: Step 1: Preparation of standard solutions of terpenoids and sterols. Detection is performed using a general-purpose high-performance liquid chromatograph, eliminating the need for large-scale precision mass spectrometry equipment, resulting in lower purchase and maintenance costs. The operation process is simple and easy to learn, meeting the needs of high-throughput rapid detection of batch samples. A single sample test only takes 35-60 minutes, significantly improving detection efficiency. It can simultaneously complete the qualitative identification and content determination of five target components, including lupeol and taraxasterol. The method has good repeatability and high accuracy, with excellent linearity of the standard curve, and stable and reliable detection results. By optimizing the extraction solvent, temperature, time, and isocratic elution chromatographic conditions, the target components are fully extracted and separated effectively, allowing for accurate acquisition of the content data of each component.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof, wherein - - - - -, R1, R2, R3a, R3b, R4a , R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The purpose of the present invention is to provide lipid nanoparticles capable of efficiently introducing a nucleic acid into T cells. Provided are lipid nanoparticles each comprising: a nucleic acid encapsulated in each of the lipid nanoparticles; a cationic lipid; sterol or a sterol derivative; DSPC; a targeted polyalkylene glycol-modified lipid linked to a target binding site; and a non-targeted polyalkylene glycol-modified lipid to which the target binding site is not linked. The target binding site targets a target site on each T cell. The amount of the cationic lipid is 35.0-55.0 mol% with respect to the total lipid amount of the lipid nanoparticles. The amount of sterol is 25.0-40.0 mol% with respect to the total lipid amount of the lipid nanoparticles. The amount of DSPC is 15.0-35.0 mol% with respect to the total lipid amount of the lipid nanoparticles. The N / P ratio is 8.0-12.0.

The application discloses a kind of nanocarrier of cosmetic active substance, micro-nano flow control preparation method and application, it is related to nanocarrier technology and cosmetic field.The application includes the following steps: S1, preparation of lipid phase, phospholipid and sterol are uniformly dissolved in ethanol, obtain lipid phase;S2, preparation of water phase, cyanate fruit polysaccharide and polypeptide are uniformly dissolved in distilled water, after uniform dissolution, centrifugation, take supernatant, obtain water phase;S3, preparation of nanocarrier, lipid phase and water phase are transported to the inside of micro-nano flow control chip and combined, lipid phase and water phase are combined to form nanocarrier in the inside of micro-nano flow control chip, obtain precursor solution containing nanocarrier;S4, screening nanocarrier, precursor solution is reduced pressure distillation, then centrifugal removal organic solvent and free un-wrapped component, obtain nanocarrier.Polypeptide is dissolved in water phase, can keep the active conformation of polypeptide peptide chain in larger amount, so that nanocarrier can deliver active substance to the specified structure layer of skin.

The application provides application of cholesterol in preparation of a feed additive, a feed and a preparation method, and comprises the application of cholesterol or a feed-acceptable ester thereof in preparation of a feed additive for crustaceans, is used for regulating lipid metabolism of the crustaceans, and improves the antioxidant capacity of the crustaceans. The content of animal protein source in the feed is not higher than 30%. In the application, the cholesterol is added in the feed of the crustaceans as a functional additive of sterols in a low dose, on the one hand, effective addition of the cholesterol can significantly improve the growth performance of the crustaceans under the condition of low fish meal feed, on the other hand, the lipid metabolism and the antioxidant capacity of the crustaceans can be regulated, and the physiological health is maintained.

Oligonucleotides and compositions including the same are disclosed that modulate (e.g., inhibit, limit or reduce) sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) activity. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders, and / or conditions associated with SCAP activity such as nonalcoholic fatty liver disease (NAFLD), (NASH), dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), and / or other SCAP-associated conditions, diseases, and / or disorders.

A sterol-based compound of formula (I) for its use in preventing, ameliorating and / or treating a mitochondrial deficiency-related pathology chosen from the group consisting of autism, spinal cord injury, multiple sclerosis, epilepsy, migraine, alcohol-related mental pathologies, ataxia, neuropathies, smoking-related cerebral and pulmonary disorders, MERRF syndrome and NARP syndrome. A pharmaceutical composition comprising at least one compound of formula (I).

Provided herein is a lipid nanoparticle comprising an encapsulated oligonucleotide molecule, wherein the oligonucleotide molecule is single-stranded or double-stranded and has a length of between 5 and 500 nucleotides; and 20 to 70 mol % of a neutral lipid content relative to total lipid present in the lipid nanoparticle, an ionizable lipid; a sterol; and optionally a hydrophilic polymer-lipid conjugate.

This invention provides an ionizable lipid molecule, its preparation method, and its application, as well as lipid nanoparticles and their applications, belonging to the field of medicinal chemistry technology. This invention provides an ionizable lipid molecule, a novel type of ionizable lipid molecule, LNP prepared by combining it with non-cationic lipids, sterols, and polyethylene glycol lipids, which can improve the delivery efficiency of nucleic acid drugs loaded with it and has low toxicity. Data from the examples show that it has excellent ability to deliver nucleic acids into cells in both in vitro and in vivo delivery, and is significantly superior to the USFDA-approved positive control (SM-102) aminolipids.

This disclosure provides unshielded lipid nanoparticles and a method for producing such unshielded lipid nanoparticles, thereby overcoming the challenge of preparing particles without causing their aggregation. The lipid nanoparticles comprise nucleic acid cargo molecules; sterols or derivatives thereof present in an amount of at least 12% molar ratio; neutral lipids, such as phospholipids having a choline head group, in an amount of 22% to 65% molar ratio; and ionizable cationic amino lipids in an amount of 15% to 45% molar ratio; wherein the lipid nanoparticles are not sterically stabilized by a hydrophilic polymer-lipid conjugate or are unshielded, and wherein each % molar ratio is relative to the total lipids present in the lipid nanoparticles.

The application belongs to the technical field of biological medicine, and discloses an antioxidative ionizable cationic lipid as well as a preparation method and application thereof. The ionizable cationic lipid with ionizable characteristics, antioxidative property and reactive oxygen species (ROS) scavenging capacity is efficiently synthesized by introducing a single-sulfur or double-sulfur heterocyclic structure unit through a four-component Ugi reaction. Based on the lipid, solid sterol, phospholipid and polyethylene glycol lipid form a lipid nanoparticle, which can be used for nucleic acid drug delivery, significantly improves the antioxidative property and nucleic acid transfection efficiency, and reduces the inflammatory response, and can meet the application requirements of mRNA therapy, nucleic acid vaccine and gene editing, and has very important significance for expanding the clinical application of mRNA therapy, nucleic acid vaccine and gene editing therapy.

This invention discloses a method for removing aflatoxin from peanut oil, belonging to the field of edible oil production technology. The core steps of this method include: first, activating and modifying sodium-based montmorillonite acid, then compounding it with silica in a specific ratio to form a composite adsorbent, while simultaneously preheating the peanut oil; adding the composite adsorbent to the preheated peanut oil, and completing initial adsorption under specific conditions; subsequently, enhancing the adsorption of aflatoxin by the adsorbent through a three-stage gradient power and temperature microwave-assisted treatment; finally, removing the adsorbent through solid-liquid separation. Vacuum deodorization can be added as needed to enhance the flavor of the peanut oil. This invention not only achieves deep removal of aflatoxin from peanut oil but also reduces the loss of nutrients such as total tocopherols and total sterols; moreover, the equipment used in the process is conventional food processing equipment, with simple parameter control, and can be directly integrated into existing peanut oil production lines, combining safety, economy, and industrial adaptability.

This disclosure relates to compositions comprising glycolipid nanoparticles and a therapeutic comprising: a) ionizable lipid, b) poly(ethylene glycol) lipid, c) sterol, and d) glycolipid. In certain embodiments, the average diameter of the particles is about between 30 and 180 nm. In certain embodiments, the therapeutic is a nucleic acid encoding a therapeutic protein.

The present disclosure provides a lipid nanoparticle comprising: nucleic acid cargo; ionizable lipid; non-polar, neutral lipid, such as a phospholipid; non-polar lipid, such as a glyceride; and sterol, the lipid nanoparticle being unshielded and wherein each mol% content is relative to total lipid present in the lipid nanoparticle.

The application discloses a nucleic acid lipid nanoparticle preparation, a preparation method thereof and application thereof, and particularly discloses a lipid nanoparticle preparation which comprises a lipid nanoparticle and a freeze-drying protective agent; the lipid nanoparticle comprises a lipid carrier and a nucleic acid; the lipid carrier comprises an ionizable lipid compound or a pharmaceutically acceptable salt thereof, a phospholipid, a sterol and a PEG lipid; the ionizable lipid compound is a compound shown in formula I. The nucleic acid lipid nanoparticle preparation of the application has good lipid nanoparticle integrity, better physical and chemical properties or better biological activity after reconstitution of the freeze-dried preparation.

The present invention addresses the problem of providing: lipid nanoparticles that enable selective delivery of a nucleic acid to a target cell; or a method for measuring the optimal density for selective delivery of a nucleic acid to a target cell. Provided are lipid nanoparticles that include: a nucleic acid encapsulated in the lipid nanoparticles; a cationic lipid; a sterol or a sterol derivative; an antibody selected from a VHH antibody, an Fab antibody, and an scFv antibody; a targeting polyalkylene glycol-modified lipid; and a non-targeting polyalkylene glycol-modified lipid. The antibody targets an antigen on a T-cell. The targeting polyalkylene glycol-modified lipid is a lipid in which the antibody is linked to polyalkylene glycol. The non-targeting polyalkylene glycol-modified lipid is a lipid not linked to the antibody. The density of the VHH antibody existing on the surfaces of the lipid nanoparticles in a state capable of binding to the antigen is 0.004-2.300 per 100 nm2 of the nanoparticle surfaces. The density of the Fab antibody existing on the surfaces of the lipid nanoparticles in a state capable of binding to the antigen is 0.003-1.113 per 100 nm2 of the nanoparticle surfaces. The density of the scFv antibody existing on the surfaces of the lipid nanoparticles in a state capable of binding to the antigen is 0.003-1.113 per 100 nm2 of the nanoparticle surfaces.

This application discloses liposomes encapsulating LBP, their preparation method, and applications, belonging to the field of biomedical technology. The liposome comprises a phospholipid bilayer, with LBP encapsulated within the lumen of the phospholipid bilayer. The phospholipid bilayer is formed of a mixture of lipids, consisting of cationic lipids, neutral accessory lipids, and sterols, wherein the neutral accessory lipid is dipalmitoyllecithin. This liposome achieves a synergistic protective effect in the treatment of acute lung injury through a strategy of combining DPPC in the lipid membrane with LBP encapsulation, exhibiting excellent lung targeting and immune safety, thereby providing a new approach for the application of LBP protein in the treatment of acute lung injury and improving the therapeutic efficacy of acute lung injury.

This document describes compositions and methods for delivering nucleic acids (e.g., DNA) into cells. In some embodiments, these compositions and methods involve the use of lipid nanoparticles comprising cationic lipids, auxiliary lipids, conjugated (PEG) lipids, and structural (sterol) lipids, wherein the auxiliary lipids have at least one acyl chain with unsaturation, which improves the in vivo delivery of nucleic acid payloads.